妊娠期使用生物制剂对婴儿疫苗接种影响的研究进展

Effects of Maternal Biologics Use on Infant Immunization:Recent Research Progress

育龄期女性是自身免疫性疾病的高发人群,其发病率在1.5~10例/万人。生物制剂作为该类疾病的新兴治疗手段,由于其疗效确切、不良反应小,亦在育龄期妇女广泛使用。研究显示,不同生物制剂在穿透胎盘屏障方面差异显著。目前,世界卫生组织(WHO)及美国儿科学会(AAP)尚未对妊娠期生物制剂暴露婴儿提出统一的疫苗接种方案。本文拟对育龄期女性在妊娠期选择不同的生物制剂、对胎儿及疫苗免疫应答的影响进行综述,旨在为临床决策提供更明确的指导,促进母婴健康高质量发展。

Women of childbearing age are at a heightened risk for autoimmune diseases,with an incidence rate ranging from 1.5 to 10 cases per 10000 individuals.Biologic agents,recognized for their efficacy and minimal adverse effects,are commonly utilized in this population.Research indicates significant variability among different biologic agents regardingtheir ability to cross the placental barrier.Currently,the World Health Organization(WHO)and the American Academy of Pediatrics(AAP)have not established a standardized vaccination protocol for infants exposed to these agents during pregnancy.This article aims to review the selection of biologic agents by pregnant women and their effects on fetal development and vaccine immune responses.The goal is to provide clearer guidance for clinical decision-making and to enhance maternal and infant health outcomes.